Resistance to chemotherapeutic drugs is a significant clinical problem in the treatment of cancer and this resistance has been linked to the cellular expression of multidrug-efflux transporters. The aim of this study was to explore the role of HOXC6 in the regulation of multidrug resistance (MDR) to chemotherapeutic drugs. The HOXC6 gene was identified as being overexpressed in drug-resistant cells compared with parental cell lines. Transfection assays demonstrated that HOXC6 activated MDR-1 promoter activity. A series of MDR-1 promoter deletion mutants was examined and the minimal HOXC6-responsive region was identified to be in the TAAT motif ( À 2243 bp) of the MDR-1 promoter. Interestingly, overexpression of HOXC6 in the parental cell lines resulted in the upregulation of MDR-1 expression. The inhibition of HOXC6 using small interfering RNA led to the repression of MDR-1. We determined that knockdown of HOXC6 expression in MDR cells increased their sensitivity to paclitaxel. Flow cytometry analysis suggested that siHOXC6 could induce paclitaxel-induced apoptosis and that this was accompanied by an increased accumulation and a decreased release of paclitaxel. Taken together, our findings suggest that HOXC6 expression is an important mechanism of chemotherapeutic drug resistance via its regulation of MDR-1.
INTRODUCTION
The homeobox (HOX) genes belong to the homeoprotein family of transcription factors, which have an important role in morphogenesis and cellular differentiation during the embryonic development of all multicellular organisms. [1] [2] [3] [4] There are 39 different human HOX genes that are clustered into four different groups (HOXA, HOXB, HOXC, and HOXD). 1, 2 Recent studies have demonstrated that HOX gene expression is deregulated in many tumor types, including lung, breast, ovarian, sarcoma and leukemia. 1, 5 Although HOX genes are overexpressed in various tumors and organisms, their functional differences are unknown.
The HOX family member HOXC6 is associated with several human carcinomas, including gastrointestinal, breast, lung and prostate, and HOXC6 is overexpressed in osteosarcomas and medulloblastomas. [6] [7] [8] [9] [10] It has been demonstrated that HOXC6 is expressed in response to hormonal signals and that the level of HOXC6 expression varies based on developmental stage. 3, 11 In LNCaP cells, small interfering RNA (siRNA) knockdown of HOXC6 expression induces apoptosis, and the overexpression of HOXC6 results in increased proliferation and decreased apoptosis. 12 In a recent study, HOXC6 was shown to have an important role in several cellular events including prostate branching morphogenesis and bone metastasis through the regulation of its functional biological targets. Several HOXC6 functional targets include CD44, T-cell receptor alternate reading frame protein, insulin-like growth factor binding protein 3, and neutral endopeptidase/membrane metallo-endopeptidase. 13, 15 In addition, HOXC6 has been reported to modulate the expression of bone morphogenic protein 7, fibroblast growth factor receptor 2, and platelet-derived growth factor receptor a and to regulate the PI3K/Akt, Notch and Wnt signaling pathways. [13] [14] [15] [16] [17] Although HOXC6 is critical for various regulated cellular processes and correlates with cancer progression, the function of HOXC6 is largely unknown.
Cancer chemotherapy is limited by acquired MDR, which is resistance to multiple structurally, mechanistically and functionally unrelated anticancer drugs. 18, 19 The overexpression of drug efflux transporters, including the ATP-binding cassette (ABC) membrane transporters such as P-glycoprotein (ABCB1/MDR-1; Pgp), MDR protein 1 (ABCC1/MRP-1), and the breast-cancer resistance protein (ABCG2/BCRP) is recognized as a biological mechanism that contributes to multidrug resistance (MDR). 18, 20, 21 These membrane transporters pump anticancer agents out of the cell through the cell membrane to reduce intracellular drug accumulation. 22 We hypothesize that HOXC6 may regulate MDR. Here, our data provided novel evidence that HOXC6 induces the expression of MDR-1 in MDR cells. MDR-1 was identified as a direct regulatory target of HOXC6 in MDR cell lines. We have also identified some of HOXC6's biological function, including the apoptosis pathways that are directly affected by MDR-1 repression. These data suggest a potential role for HOXC6 in the regulation of chemotherapeutic drug resistance.
RESULTS

Induction of HOXC6 and MDR-1 in MDR cancer cells
In our previous study, to confirm the expression of the HOX family in the paclitaxel-resistant FaDu cell line (FaDu/PTX), reverse transcription PCR (RT-PCR) was performed using specific oligonucleotides against each of the HOX family genes (HOXA, HOXB, HOXC and HOXD). We showed that 16 of 33 HOX genes were expressed in FaDu/PTX and parental cells. Of these 16 expressed genes, two HOX genes (HOXA5 and HOXC6) were importantly expressed in FaDu/PTX compared with parental cell. The other 14 HOX genes (HOXA4, HOXA6, HOXA10, HOXA11, HOXB6, HOXB13,  HOXC9, HOXC10, HOXC11, HOXC13, HOXD8, HOXD9, HOXD10 and  HOXD11) were downregulated in FaDu/PTX cells. The remaining 17 of 33 HOX genes were not detectable in both the cell lines. One of these two expressed HOX genes (HOXA5) were slightly expressed in FaDu/PTX cells. Of particular interest, the expression of HOXC6 was found to be significantly higher in FaDu/PTX cells than in the parental cells (Supplementary data 1) . Therefore, human MDR cancer cell lines were used in an initial screen to identify potential associations between HOXC6 and MDR genes related to drug resistance.
In this study, RT-PCR constantly showed that HOXC6 was upregulated in FaDu/PTX cells and other drug-resistant cancer cell lines (MCF-7/ADR and SNU601/CIS) compared with the parental cells ( Figure 1a ). The expression of MDR genes, which are involved in MDR, was evaluated by RT-PCR using specific primers. The mRNA and protein expression levels of MDR-1 were relatively higher in FaDu/PTX, SNU601/CIS and MCF-1/ADR cells than in the parental cell lines (Figures 1b and c) . In addition, quantitative RT-PCR analysis indicated that HOXC6 and MDR-1 were significantly upregulated in three MDR cell lines (Figure 1d ). The ratio of HOXC6 mRNA expression was46-fold in all MDR cell lines, and the highest ratio was a ninefold increase, as determined using real-time RT-PCR. Similarly, MDR-1 mRNA was increased in these cell lines (Figure 1d ). However, unlike MDR-1, no characteristic patterns in MRP-1 and BCRP expression were observed in these cell lines.
To test the effect of HOXC6 expression on MDR-1 promoter activity, we generated a luciferase reporter construct driven by the 3 kb MDR-1 promoter. Parental and MDR cancer cells were transiently transfected with the MDR-1 promoter-luciferase reporter gene or an empty reporter vector. The higher endogenous expression of HOXC6 in MDR cancer cells (FaDu/PTX, SNU601/ CIS, and MCF-1/ADR) is associated with higher MDR-1 promoter activity (Figures 1e, f, and g ). These results are in agreement with our data from the real-time RT-PCR experiments, indicating that HOXC6 regulates MDR-1 expression in a positive manner.
Overexpression of HOXC6 induces the upregulation of MDR-1 mRNA levels and increases drug resistance It was previously demonstrated that HOXC6 indirectly regulates the Notch signaling pathway, 13 and that Notch-1 is involved in MDR-1 expression. 23 To determine whether Notch-1 is involved in MDR-1 expression, we measured Notch-1, Notch-2 and Hes-1 (a major target of Notch-1). We observed higher levels of Notch-1 and Notch-2 proteins in the FaDu/PTX cells compared with the parental FaDu cells (Figure 2a ). As expected, the higher Notch expression in HOXC6-expressing FaDu cells was associated with higher Notch activity (fourfold) as measured by Hes-1 promoter activity (Figure 2b ). However, mRNA levels of MDR-1 in Notch intracellular domain (NICD) (the cleaved form of the Notch-1 protein)-overexpressing FaDu cells were not affected (Figure 2c ). These results indicate that HOXC6-induced Notch did not affect the expression of MDR-1.
We then examined whether the overexpression of HOXC6 in the parental cells (FaDu, MCF-7 and SNU601) could affect the expression of MDR-1 and drug resistance. We observed higher levels of HOXC6 proteins in the HOXC6-transfected cells compared with the control cells. Remarkably, the overexpression of HOXC6 caused an increased expression of MDR-1 mRNA in FaDu cells (Figure 2d) . A quantitative evaluation of HOXC6 overexpression was determined in FaDu cells at 48 h after pcDNA3-HOXC6 using flow cytometry (Figure 2e ). In addition, we observed higher levels of MDR-1 promoter activity (an B6-fold increase compared with control cells) when HOXC6 expression was induced (Figures 2f, g  and h) . The proliferation inhibition rate of HOXC6-transfected FaDu cells treated with or without paclitaxel was detected using an MTT assay. These results showed that HOXC6 overexpression increased the resistance of FaDu cells to paclitaxel (Figure 2i ). siRNA targeting HOXC6 induces intracellular Rhodamine 123 accumulation To determine the effect of HOXC6 depletion in MDR cells, we downregulated HOXC6 using siRNA transfection and determined the in vitro anticancer drug sensitivities of each cell line. We prepared total RNA and whole-cell protein lysates at 48 h post transfection. Parallel transfections using scramble siRNA were used as negative controls. Western blotting indicated that HOXC6 expression was decreased in siHOXC6-transfected MDR cells. HOXC6 siRNA inhibited MDR-1 mRNA expression in MDR cells compared with the scramble siRNA -transfected cells (Figure 3a) . quantitative RT-PCR confirmed that expression of the MDR-1 transcript was inhibited in siHOXC6-transfected MDR cells (Figure 3b ). In addition, we observed suppression (B4-fold relative to the control) of MDR-1 promoter activity when HOXC6 expression was inhibited in FaDu/PTX cells (Figure 3c ). These results were similar in both MCF-7/ADR and SNU601/CIS cell lines (Figures 3d and e) .
To determine whether the inhibition of HOXC6 expression was sufficient to sensitize the drug-resistant FaDu/PTX cells to chemotherapy, an additional experiment was performed. FaDu/ PTX, MCF-1/ADR and SNU601/CIS cells were transfected with HOXC6 siRNA and administered Rho123. The cells were counted at 48 h post transfection. Rho123 accumulation increased after the administration of verapamil with Rho123 (positive control) compared with the negative control (without Rho123 treatment). The siHOXC6-transfected cells had significantly higher levels of Rho123 accumulation than the control cells (Figures 3f, g and h) .
Identification of the HOXC6-binding site in the MDR-1 promoter We have demonstrated that HOXC6 can activate the MDR-1 promoter-reporter activity; however, it is not known which region of the MDR-1 promoter is directly responsible for HOXC6 activation. We next attempted to define the binding sites of HOXC6 in the MDR-1 promoter by serially deleting regions within the promoter. AtB3 kb immediately upstream of the MDR-1 transcriptional start site, we identified several potential HOX binding sites. We constructed a series of deletions aimed at removing these sites in a stepwise manner. As depicted in Figure 4a , the deletion constructs pGL3-MDR-1-3001 and pGL3-MDR-1-2859 had no drastic effects on their ability to bind HOXC6. However, the deletion construct, pGL3-MDR-1-1966 demonstrated a dramatically decreased ability to be activated by HOXC6. These data suggest that there may be critical binding sites for HOXC6 in the MDR-1-2859 bp promoter region.
It was previously demonstrated that HOXC6 is a member of the HOX family of transcription factors, which bind to HOX corebinding motifs (TAAT) of target gene promoters to regulate gene expression. 6 According to the MDR-1 promoter sequence analysis of the region from À 2859 to À 1966 bp, there are five tentative TAAT element binding sites for HOXC6 (Figure 4b ).
To determine which binding site is responsible for MDR-1 promoter activation by HOXC6, four MDR-1 promoter deletion mutants were generated using MDR-1-2859 bp as a template. We named the four mutants with deleted TAAT elements as pGL3-MDR-1-P1, pGL3-MDR-1-P2, pGL3-MDR-1-P3 and pGL3-MDR-1-P4 (Figures  4b and c) . As indicated in Figure 4c , the pGL3-MDR-1-P3 deletion mutant inhibited HOXC6 activation of the MDR-1 promoter. Thus, these results revealed that the À 2243 bp TAAT motif located in the À 2859 bp to À 1966 bp region of the MDR-1 promoter was responsible for MDR-1 promoter activation by HOXC6.
To confirm the binding of HOXC6 to the MDR-1 promoter, we performed a chromatin immunoprecipitation assay. The crosslinked extracts were immunoprecipitated with antibodies against HOXC6 or control anti-IgG antibody. The cross-linked DNA was analyzed using PCR with primers designed to amplify the HOXC6-responsive region, which covered the TAAT motif ( À 2243 bp) of the MDR-1-2859 bp promoter. Compared with the IgG control group, HOXC6 was determined to be associated with the MDR-1 promoter region containing the TAAT motif ( Figure 4d ). The MDR-1 promoter-reporter plasmid containing a mutation of the TAAT motif ( À 2243 bp) was constructed. The wild-type (pGL3-MDR-1-3001) and mutated reporters were transfected into MDR cells to analyze promoter activity. Interestingly, the mutated TAAT motif reduced MDR-1 promoter activity relative to the wild-type promoter, indicating HOXC6 specificity to the sequence containing TAAT (Figures 4e, f and g).
HOXC6 siRNA reverses drug resistance and induces apoptosis in FaDu/PTX cells To investigate whether drug resistance can be reversed by reducing MDR-1 activity/levels in siHOXC6-transfeced cells, we treated the MDR cells with either a non-toxic dose of chemotherapeutic drugs or HOXC6 siRNA to knock down HOXC6 expression levels. We then tested cell viability for changes in drug sensitivity. Western blotting indicated that HOXC6 expression decreased in siHOXC6-transfected FaDu/PTX cells. The viability of the FaDu/PTX cells was slightly decreased by paclitaxel compared with untreated cells. Similarly, HOXC6 siRNA slightly inhibited cell viability in the FaDu/PTX cells compared with the scramble siRNA -transfected cells. These results were similar in both MCF-7/ADR and SNU601/CIS cell lines (Figure 5a ). Interestingly, treatment with siHOXC6 combined with paclitaxel significantly inhibited cell proliferation compared with siHOXC6 or paclitaxel alone. These results strongly support the hypothesis that HOXC6 exerts its effect on MDR-1-mediated drug responsiveness.
To support these results, we investigated the effect of siHOXC6 and PTX on apoptosis induction in FaDu/PTX cells using flow cytometry analysis. We determined that apoptosis was slightly induced by siHOXC6 treatment in FaDu/PTX cells. Exposure of the cells to siHOXC6 with paclitaxel (400 nM) caused increased apoptosis (34%) compared with siHOXC6-treated cells (11%; Figure 5b ), supporting the results of the MTT assay. In addition, similar apoptosis was observed in both the MCF-7/ADR and SUN601/CIS cell lines (data not shown).
To determine caspase activation during apoptosis in FaDu/PTXsiHOXC6 cells, we investigated caspase-3 activity after the cells were treated with paclitaxel and/or siHOXC6. The colorimetric assay revealed that caspase-3 activity was remarkably increased in the FaDu/PTX-siHOXC6 cells. Indeed, the caspase-3 activity in FaDu/PTX-siHOXC6 cells treated with paclitaxel was significantly higher than in the FaDu/PTX-siHOXC6 cells (Figure 5c ). Poly (ADPribose) polymerase cleavage was examined by western blotting. siHOXC6-transfected MDR cells (FaDu/PTX, MCF-7/ADR, and SUN601/CIS) treated with paclitaxel, doxorubicin or cisplatin had strongly increased levels of cleaved poly (ADP-ribose) polymerase, suggesting that these cells undergo apoptosis (Figures 5d, e and f) . Our results suggest that the downregulation of HOXC6 in MDR cells improves their sensitivity to chemotherapeutic drugs by initiating the apoptosis pathway. DISCUSSION HOX transcription factors are essential for embryonic development and have critical roles in apoptosis, differentiation and proliferation. 1, 2, 12 HOXC6 is crucial to the development and proliferation of epithelial cells in response to hormonal signals. Deregulation of HOXC6 has been detected in many cancer types such as prostate, breast and lung cancers. 3, 7, 10, 22, [24] [25] [26] However, the mechanism by which HOXC6 regulates target genes is not well understood. The resistance of chemotherapeutic drugs in cancer seems to be much more complicated, as both losses and gains in many HOX gene expression is related to tissue development or carcinogenesis. Our results suggested that the one or more of these HOX genes can be related to MDR in cancer cells. In Supplementary data Figure 1 , the fourteen HOX genes (HOXA4, Chromatin was prepared and immunoprecipitated with specific antibodies against HOXC6 or IgG. The input DNA and DNA isolated from the precipitated chromatin were amplified by PCR using Taq polymerase and separated on a 1.5% agarose gel. Lanes: M, marker; 1, input; 2, HOXC6 antibody; 3, IgG (negative control). (e-g) pGL3-MDR-1 promoter assay with TAAT motif ( À 2243 bp) point mutation constructs in FaDu/PTX, MCF-7/ADR and SNU601/CIS cells. FaDu/PTX, MCF-7/ADR and SNU601/CIS cells were transfected with wild-type pGL3-MDR-1 promoter or point mutated pGL3-MDR-1 (as indicated). pRL(Renilla luciferase) plasmid was cotransfected as an internal control. The cells were harvested 48 h after transfection. The promoter activity of each preparation was normalized to the Renilla value. The relative promoter activity is averaged from at least three independent experiments. The data are represented as the mean ± s.e.m. *Po0.05, **Po0.01, compared with control cells (pGL3-MDR-1-WT). A full colour version of this figure is available at the Oncogene journal online. HOXA6, HOXA10, HOXA11, HOXB6, HOXB13, HOXC9, HOXC10,  HOXC11, HOXC13, HOXD8, HOXD9, HOXD10 , and HOXD11) were downregulated in FaDu/PTX cells compared with parental cells. One possibility is that their HOX genes are hypermethylated by post-modification in MDR cancer cells. However, the current state of our knowledge about HOXC6 is insufficient to establish a precise, causal relationship between individual HOX genes and the specific cancer phenotypes or the chemotherapeutic drugs to which they contribute, or to understand how transcriptional and biological specificity can be obtained. Further studies of the specific expression patterns of HOX genes in MDR cancer cells are needed to fill these gaps in knowledge. We also showed that two After 48 h, the poly (ADP-ribose) polymerase active form was analyzed using western blotting. The blot was reprobed using monoclonal antibodies specific to actin to monitor for equal protein loading.
HOX genes (HOXA5 and HOXC6) were importantly expressed in FaDu/PTX compared with parental cell; especially the expression level of HOXC6 was higher in FaDu/PTX cells than parental cell.
In the present study, we confirmed that the expression of HOXC6 was upregulated in our MDR cell lines, including FaDu/PTX, MCF-7/ADR and SNU601/CIS cells. Moreover, using gene transfection and RNA interference techniques, we demonstrated that the in vitro drug sensitivity to paclitaxel in FaDu/PTX cells and chemotherapeutic drug-induced apoptosis were increased in cells transfected with siHOXC6. This strongly indicates that HOXC6 is involved in the regulation of MDR in MDR cancer cells.
Chemotherapeutic drug resistance is a major clinical problem and a cause of cancer treatment failure in many human cancers. Recently, various mechanisms, including the upregulation of drug efflux ABC transporters, such as P-glycoprotein (ABCB1), MDR protein 1 (ABCC1) and ABCG2 have been identified and characterized as transporting and conferring resistance to virtually the entire spectrum of cancer drugs. Therefore, the upregulation of these genes can cause MDR in cancers. [18] [19] [20] Unfortunately, there is currently no solution to MDR.
In our previous study, we attempted to elucidate the mechanism of MDR by creating a FaDu/PTX by exposing wild-type FaDu cells to increasing concentrations of paclitaxel for more than 10 months. We identified that the IC 50 values for paclitaxel in FaDu/WT and FaDu/PTX cells were 20 nM ± 3.5 and 60 mM ± 7.2, respectively. The FaDu/PTX cells also had cross-resistance to DOX (fivefold resistance; unpublished data). In addition, the mRNA expression of HOXC6 and MDR-1 was increased in FaDu/PTX cells. It has been shown that MDR-1 (Pgp) is the most important drug transporter in mammalian cells. 22 In this study, we demonstrated that the expression of MDR-1 was upregulated by HOXC6, suggesting that the upregulation of MDR-1 is likely responsible for the decrease in both drug accumulation and retention. Therefore, HOXC6 may be one of the mechanisms that confer resistance to many cancer chemotherapies.
In addition, we observed increased expression of Notch-1 and Notch-2 in FaDu/PTX cells. A recent study has suggested that Notch is involved in the transcriptional regulation of ABCC1/MRP-1 in MCF-7/VP cells and likely contributes to the ABCC1-mediated resistance to etoposide. However, this group did not investigate the connection between Notch-1 and either ABCB1/MDR-1 or ABCG2/BCRP. 23 Although our results suggest that there is increased activation/expression of Notch-1 and Notch-2 in FaDu/ PTX cells overexpressing HOXC6, Notch signaling is not directly involved in MDR-1 expression. In our study, the exact mechanism of increased Notch expression in MDR cells is not known. However, MDR cells are continuously exposed to sublethal concentrations of an anticancer drug, and consequently, MDR cells experience various epigenetic and genetic changes. Accordingly, the increased level of Notch expression in FaDu/ PTX cells may be a consequence of one of these changes.
We show, for the first time, that HOXC6 directly targets MDR-1 expression. HOXC6 is a HOX family member that presumably functions by binding directly to DNA promoter elements via its homeodomain, which is a DNA-binding domain located within its N-terminus. 27 The DNA core sequence of the homeodomainbinding sites frequently contains the sequence TAAT. In this study, the results of the promoter deletion mutants confirm that HOXC6 directly binds to the specific TAAT-a sequence motif in the MDR-1 gene promoter. Previous studies also showed that HOXC6 bound to similar elements on the neural cell adhesion molecule promoter. 28 This promoter also contains the TAAT-a motif. Our studies define HOXC6-binding elements as being critical for mediating the transcriptional activation of the MDR-1 promoter by HOXC6. The TAAT element deletion mutants (pGL3-MDR-1-P3 and pGL3-MDR-1-P4) reduced HOXC6-directed activation of the MDR-1 promoter by B60%, and mutating this element nearly abolished the response (Figure 4) . Chromatin immunoprecipitation approaches clearly demonstrated that endogenous HOXC6 was associated with the TAAT motif in the native MDR-1 promoter in FaDu/PTX, MCF-7/ and SNU601/CIS cells. These studies support the established HOXC6 mechanism that involves direct binding of HOXC6 to specific promoter elements to activate MDR-1 expression in MDR cells. Moreover, siRNA directed against HOXC6 resulted in decreased MDR-1 mRNA levels and reduced luciferase reporter activity in MDR cells. Therefore, we believe that HOXC6 induces MDR-1 expression in MDR cancer cells by directly increasing its promoter activity.
HOXC6 could be acting both to prevent apoptosis and to promote cell cycle progression. The silencing of HOXC6 expression using siRNA resulted in decreased cell proliferation and the induction of apoptosis in prostate cancer cells. 12 Our results demonstrate that HOXC6 siRNA can effectively downregulate HOXC6 overexpression in FaDu/PTX, MCF-7/ADR and SNU601/CIS cells. However, the siRNA suppression of HOXC6 was not strongly correlated with the induction of apoptosis in these cells. This differential response may be due to differences in the many target molecules and signaling pathways in various cancer cell lines. Therefore, the roles of HOXC6 differ across a variety of MDR cell lines. Our findings suggest that the silencing of HOXC6 sensitizes MDR cells to chemotherapeutic drugs by downregulating MDR-1 expression. In FaDu/PTX, MCF-7/ADR and SNU601/CIS cells, treating cells with siHOXC6 combined with paclitaxel, doxorubicin and cisplatin significantly induced apoptosis compared with siHOXC6 or PTX alone. These results strongly support the hypothesis that HOXC6 exerts its effect on MDR-1-mediated drug responsiveness. In future studies, we will test the unique expression and function of HOX gene confirmed in the present study in tissues from different chemotherapeutic drugresistant patients. We believe will provide considerable evidence to our understanding of the relationship of deregulated HOX gene family and MDR in cancer and the functions of HOXC6 genes in general and specific phenotypes of MDR cells.
In conclusion, this study provided multiple lines of evidence indicating that HOXC6 increases resistance to chemotherapeutic drugs by inducing MDR-1, suggesting that HOXC6 could serve as a therapeutic target for MDR cancer. Further identification of other HOXC6 regulatory targets will provide us with a better understanding of how HOXC6 signaling pathways contribute to altering the MDR/sensitivity and survival of cancer cells.
MATERIALS AND METHODS
Cell cultures
The cell culture media (Dulbecco's modified Eagle's medium, minimum essential medium (MEM), and RPMI-1640) were supplemented with 10% FBS, 100 units/ml penicillin, and 100 mg/ml streptomycin. The cells were cultured in a humidified incubator in an atmosphere of 95% air and 5% CO 2 . The MCF-7 wild-type (MCF-7/WT) and adriamycin-resistant MCF-7 cell lines (MCF-7/ADR) were cultured in Dulbecco's modified Eagle's medium (GIBCO, Grand Island, NY, USA). The FaDu human oral cancer cell line and paclitaxel-resistant FaDu cells (FaDu/PTX) were maintained in minimum essential medium (GIBCO). The human gastric cancer cells, SNU601, and the cisplatin-resistant SNU601 cells (SNU601/CIS) were maintained in RPMI-1640 medium (GIBCO).
RNA purification and RT-PCR
Total RNA was isolated from both parental and drug-resistant cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). To avoid genomic DNA contamination, the extracted RNA was purified using the RNeasy kit (Invitrogen). The quantity and quality of the RNA were determined by measuring the optical density at 260 and 280 nm. Two micrograms of RNA were used for cDNA synthesis using oligo-(dt) 15 primer and MoloneyMurine Leukemia Virus (M-MLV) reverse transcriptase. The RT reaction began with 10 min incubation at room temperature followed by 42 1C for 60 min, and 10 min at 70 1C to terminate the reaction. Subsequently, 2 ml aliquot of cDNA was PCR-amplified in a total volume of 25 Table 1 . The PCR products were analyzed using gel electrophoresis with 1.2% agarose gel.
Quantitative real-time PCR
Quantitative real-time PCR was performed using SYBR Green (Applied Biosystems, Foster City, CA, USA). PCR runs and fluorescence detection were performed in a Rotor-Gene 6000 Real-Time PCR system (Corbett Research, Sydney, NSW, Australia). On the basis of HOXC6, MDR-1 and glyceraldehyde 3-phosphate dehydrogenase cDNA sequences information (GenBank accession numbers: NM_004503.3, NM_000927.4 and NM_002046.3, respectively), two pairs of gene-specific primers were designed. The reaction mixture contained 10 ng of cDNA diluted in 2.5 ml of DEPC-treated water, 5 ml Power SYBR Green PCR Master Mix (2 Â ; Applied Biosystems), and 2 ml of gene-specific primers (final concentration 50 nM each), in a final reaction volume of 10 ml. The sequences of the real-time PCR primers were as follows: HOXC6: forward 
MTT assay
Briefly, the cells were seeded at 1 Â 10 5 cells per well into 12-well plates. Before testing, the MTT solution (5 mg/ml in PBS) was added, and the cells were incubated at 37 1C for 3 h (h). The culture medium was aspirated and an acid-isopropanol mixture (0.04 mol/l HCl in isopropanol) was added to dissolve the dark blue crystals. The optical density value of the dissolved solute was measured using a Microplate Autoreader at a wavelength of 570 nm.
Plasmid constructs and subcloning
Subcloning was performed as previously described, with some modifications. 29 The progressive deletion fragments of the MDR-1 promoter region were generated using PCR with human genomic DNA as the template and were subcloned into the KpnI and NheI sites of the pGL3 vector. Both the full-length and deleted MDR-1 promoter sequences were PCR-amplified using the primers listed below. Forward primers: pGL3-MDR-1-3001 bp, 
MDR-1 promoter-luciferase reporter assay
The pGL3-3067 MDR-1 promoter construct served as a template to generate the pGL3-2922, pGL3-2032 and pGL3-1457 deletion constructs. We also used the pGL3-2922 MDR-1 promoter construct as the template to generate a deletion construct in which the four putative HOXC6-binding sites were deleted (pGL3-P1, pGL3-P2, pGL3-P3 and pGL3-P4). Luciferase reporter assays were performed as described previously. 30 The cells were grown in 12-well plates and cotransfected with MDR-1 promoter-luciferase plasmid DNA and either pCDNA3.1-HOXC6 or HOXC6 siRNA. After 48 h, cell lysates were analyzed for luciferase activities. The luciferase reporter assays were performed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) following the manufacturer's instructions. Each experiment was performed in triplicate and repeated twice.
Quantitative evaluation for HOXC6 expression
FaDu cells were transiently transfected with pcDNA3-HOXC6 and allowed to grow for an additional 48 h. FaDu cells were harvested by trypsinization and fixed in 4% paraformaldehyde for 10 min at 25 1C. The cells were permeabilized with methanol for 2 min and incubated for 2 h with HOXC6 antibody (1:100). Goat anti-rabbit IgG-FITC (Vector Laboratories Ins, Burllingame, CA, USA) was used as secondary antibody. After washing and resuspending, the cells were immediately measured by flow cytometry.
Chromatin immunoprecipitation Assay
The FaDu/PTX cells were grown to nearly 80% confluence and cross-linked with formaldehyde (Sigma, St Louis, MO, USA) at room temperature for 10 min. The cross-linked chromatin was prepared with a commercial ChIP assay kit (EZ-Magna ChIP; Millipore, Billerica, MA, USA) and immunoprecipitated using 4 mg of normal rabbit anti-IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 4 mg of anti-HOXC6 antibody (Santa Cruz Biotechnology). The HOXC6-binding site was PCR-amplified using the input DNA or DNA isolated from the precipitated chromatin as the template in combination with primers flanking the putative HOXC6-binding sites in the MDR-1 promoter. The primer sets used for the amplification of the MDR-1 promoter regions were obtained from BIONEER Co (Daejeon, Korea). The forward primer sequence was 5 0 -GAGATCATAGG CACAAATAAGA-3 0 , and the reverse primer sequence was 5 0 -AGTGTACAG CATTGTTCACTGT-3 0 .
Western blot analysis
The cell pellet was dissolved in a 1% cell lysate buffer and centrifuged for 10 min at 12 000 r.p.m. The protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockgord, IL, USA). The proteins were separated on a 10% SDS-PAGE gel and transferred to a polyvinylidene fluoride (PVDF) membrane followed by western blot analysis. A solution of 5% non-fat dried milk in TBS containing 0.1% Tween-20 was used to block non-specific binding. The membrane was subsequently incubated with an anti-HOXC6 mouse monoclonal antibody (Santa Cruz Biotechnology) or an anti-poly (ADP-ribose) polymerase antibody (Santa Cruz Biotechnology). After incubation, the blots were extensively washed in TBS containing 0.1% Tween-20. For detection, the ECL kit (Amersham Life Sciences, Arlington Heights, IL, USA) was used according to the manufacturer's instructions.
siRNA interference
The HOXC6 siRNA was obtained in the form of Silencer select validated siRNA (Applied Biosystems). The sense sequence of the HOXC6 siRNA was 5 0 -CUCGUUCUCGGCUUGUCUA (dTdT)-3 0 , and the antisense sequence was 5 0 -UAGACAAGCCGAGAACGAG (dTdT)-3 0 . The cells were transfected with siRNA (20 nM) using X-tremeGENE siRNA Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's instructions. The cells were harvested 24 h after transfection. Total cell lysates were separated by SDS-PAGE and analyzed by western blot, as described above.
Intracellular rhodamine 123 accumulation
After HOXC6 siRNA transfection, the cells were incubated for 3 h with culture medium containing 6.5 mmol/l of the fluorescent MDR-1 substrate, rhodamine 123 (Rho123). Verapamil, a known inhibitor of MDR-1-dependent transport activity, was used as a positive control. Subsequently, the adherent cells were washed five times with ice-cold PBS, and the dye was extracted by incubating each dish with 2.5 ml of n-butanol for 10 min at room temperature. The Rho123 concentrations were measured fluorometrically.
Flow cytometric cell cycle analysis and Annexin V-FITC/ propidium iodide (PI) double staining For cell cycle analysis, the cells were harvested and fixed with 70% ethanol for 1 h at 4 1C. After washing with cold PBS, the cells were incubated with DNase-free RNase and PI at 37 1C for 30 min. The specific binding of Annexin V-FITC/PI was performed by incubating the cells for 15 min at room temperature in a binding buffer (10 mM HEPES (pH 7.4), 140 mM NaCl and 2.5 mM CaCl 2 ) containing saturating concentrations of Annexin V-FITC and PI. After incubation, the cells were pelleted and analyzed using a FACScan analyzer (Beckman Coulter Inc, Fullerton, CA, USA).
Caspase-3 activity assays
The activity of caspase-3 was determined using the ApoAlert Caspase Profiling Plate (Clontech, Mountain View, CA, USA) according to the manufacturer's protocol. The release of fluorochrome aminomethyl comarin (AMC) was analyzed at an excitation of 380 nm and an emission of 460 nm using a multiplate fluorescence spectrophotometer. The data are displayed as the mean±s.e. of three independent experiments performed in duplicate and expressed in arbitrary fluorescence units/mg of protein.
Statistical analysis
Statistical analysis was performed with the data obtained from three independent experiments. The data are represented as the mean±s.e.m. A P-value o0.05 was considered significant.
